ASH 2011 Carfilzomib analyses:
"Dr. Jagannath said that even in patients with the problematic 17p13 deletion, researchers have used gene expression profiling to further delineate those at high and low risk, and that data clearly show that outcomes are improved in low-risk 17p13 deletion patients with the inclusion of the protease inhibitor bortezomib therapy."
When you order GEP how does it delineate whether a patient has a low or high risk 17p deletion?
Forums
9 posts
• Page 1 of 1
Re: RE: carfilzomib low and high risk 17 p deletion outcomes
Hallo Susie,
are there 2 different del17p13 aberrations?
which one is the problematic one?
I´m from Austria and I can´t always understand your English;
maybe you can write your knowledge about del17p13 in an easy way?
thank u so much,
KAtrin
are there 2 different del17p13 aberrations?
which one is the problematic one?
I´m from Austria and I can´t always understand your English;
maybe you can write your knowledge about del17p13 in an easy way?
thank u so much,
KAtrin
-
Katrin
Re: RE: carfilzomib low and high risk 17 p deletion outcomes
Gene expression profiling (GEP) can divide patients into high-risk and low-risk groups. del17p is always considered high-risk. These different tests usually come to similar conclusions about a patient's risk, but not always: e.g. a patient's GEP can put them in a low-risk category but they may have a del17p by FISH. What Dr. Jagannath was referring to (I believe) was that in patients who have a del17p but also a low-risk GEP, proteasome inhibitors like bortezomib may be able to improve outcomes.
As you can see, there's still more work to be done to integrate all of the different prognostic tests into a single accurate risk stratification system, but we are getting closer.
As you can see, there's still more work to be done to integrate all of the different prognostic tests into a single accurate risk stratification system, but we are getting closer.
-
Dr. Adam Cohen - Name: Adam D. Cohen, M.D.
Beacon Medical Advisor
Re: RE: carfilzomib low and high risk 17 p deletion outcomes
Thank you Dr. Cohen!!
It gives me hope that there is still more to be elucidated when it comes to risk stratification.
It gives me hope that there is still more to be elucidated when it comes to risk stratification.
-
suzierose - Name: suzierose
- When were you/they diagnosed?: 2 sept 2011
Re: RE: carfilzomib low and high risk 17 p deletion outcomes
Hi Katrin,
From what I gather, 17p is a negative no matter where it is, it is also known as TP53, and found in over 50% of cancers.
It's kinda hard to answer your question the way it is phrased but I will give it my best shot.
The way that I understand it is that 17p is the chromosome and that p stands for short arm of the chromosome then 13 stands for where the cytogenetic band is on the chromosome. The technique used to specifiy chromosomes is a flourescent stain so under the microscope you get bands. So the short coding is identifying where to locate the bands.
That's why those slides from presentations look like multi colored hues running up and down when they show them..those are the flourescent bands from the cytogenetic technique used to specifiy the chromosomes.
I tend to think of it as an apartment building where we go to the address,(17) then we decide east or west (short or long arm) in this case p, which they abbreviate as p or q, respectively. Then they tell us the specific apartment number (band) and then they tell us which room in the apartment (sub band) .
For example if it says 7q31.2, that indicates it is on chromosome 7, q arm, band 3, sub-band 1, and sub-sub-band 2.
So, to hopefully answer your question, there can be diffferent 'locales' on chromosome 17 located on the short arm of p, and those are further specificied by the band locations.
Hope that helps.
From what I gather, 17p is a negative no matter where it is, it is also known as TP53, and found in over 50% of cancers.
It's kinda hard to answer your question the way it is phrased but I will give it my best shot.
The way that I understand it is that 17p is the chromosome and that p stands for short arm of the chromosome then 13 stands for where the cytogenetic band is on the chromosome. The technique used to specifiy chromosomes is a flourescent stain so under the microscope you get bands. So the short coding is identifying where to locate the bands.
That's why those slides from presentations look like multi colored hues running up and down when they show them..those are the flourescent bands from the cytogenetic technique used to specifiy the chromosomes.
I tend to think of it as an apartment building where we go to the address,(17) then we decide east or west (short or long arm) in this case p, which they abbreviate as p or q, respectively. Then they tell us the specific apartment number (band) and then they tell us which room in the apartment (sub band) .
For example if it says 7q31.2, that indicates it is on chromosome 7, q arm, band 3, sub-band 1, and sub-sub-band 2.
So, to hopefully answer your question, there can be diffferent 'locales' on chromosome 17 located on the short arm of p, and those are further specificied by the band locations.
Hope that helps.
-
suzierose - Name: suzierose
- When were you/they diagnosed?: 2 sept 2011
Re: RE: carfilzomib low and high risk 17 p deletion outcomes
Dear Suzie,thank you for reply;
my father also have a del17p13 del on 11%
now he is in remission since february 2011
i hope he falls out of statistics
greetings
Katrin
my father also have a del17p13 del on 11%
now he is in remission since february 2011
i hope he falls out of statistics
greetings
Katrin
-
Katrin
Re: RE: carfilzomib low and high risk 17 p deletion outcomes
suzierose wrote:
> ASH 2011 carfilzomib analyses:
>
> "Dr. Jagannath said that even in patients with the problematic 17p13
> deletion, researchers have used gene expression profiling to further
> delineate those at high and low risk, and that data clearly show that
> outcomes are improved in low-risk 17p13 deletion patients with the
> inclusion of the protease inhibitor bortezomib therapy."
>
>
> When you order GEP how does it delineate whether a patient has a low or
> high risk 17p deletion?
> ASH 2011 carfilzomib analyses:
>
> "Dr. Jagannath said that even in patients with the problematic 17p13
> deletion, researchers have used gene expression profiling to further
> delineate those at high and low risk, and that data clearly show that
> outcomes are improved in low-risk 17p13 deletion patients with the
> inclusion of the protease inhibitor bortezomib therapy."
>
>
> When you order GEP how does it delineate whether a patient has a low or
> high risk 17p deletion?
-
peggylouisesmith
Re: RE: carfilzomib low and high risk 17 p deletion outcomes
Hi Peggy, I am in a carfilzomib trial for newly diagnosed myeloma. Prior to the start, they did a BMB with cytogenetics and FISH---the whole shabang. I believe that is how they classified me vis-a-vis high risk, etc. I was found to be "standard risk". However, my doctor said carfilzomib seems to work for all levels of patient risks even those with abnormalities.
-
terryl1 - Name: Terry
- Who do you know with myeloma?: self
- When were you/they diagnosed?: August 10, 2011
- Age at diagnosis: 49
Re: RE: carfilzomib low and high risk 17 p deletion outcomes
Hi Peggy!
You asked:
"When you order GEP how does it delineate whether a patient has a low or
> high risk 17p deletion?"
I am not sure.
The quote from Dr.Jagannath did not go into how that is done. My speculation is that he is referring to whether a person has trisomy, or whether they have multiple cytogenetic abnormalities in addition to the 17p deletion, but Jagannath didn't specify.
.
You asked:
"When you order GEP how does it delineate whether a patient has a low or
> high risk 17p deletion?"
I am not sure.
The quote from Dr.Jagannath did not go into how that is done. My speculation is that he is referring to whether a person has trisomy, or whether they have multiple cytogenetic abnormalities in addition to the 17p deletion, but Jagannath didn't specify.
.
-
suzierose - Name: suzierose
- When were you/they diagnosed?: 2 sept 2011
9 posts
• Page 1 of 1